Paracrine activation of hepatic stellate cells in platelet-derived growth factor C transgenic mice: Evidence for stromal induction of hepatocellular carcinoma
Jocelyn H. Wright
Department of Pathology, University of Washington, Seattle, WA
Search for more papers by this authorMelissa M. Johnson
Department of Pathology, University of Washington, Seattle, WA
Search for more papers by this authorMasami Shimizu-Albergine
Department of Pathology, University of Washington, Seattle, WA
Department of Pharmacology, University of Washington, Seattle, WA
Search for more papers by this authorRenay L. Bauer
Department of Pathology, University of Washington, Seattle, WA
Search for more papers by this authorBrian J. Hayes
Department of Pathology, University of Washington, Seattle, WA
Search for more papers by this authorJames Surapisitchat
Department of Pathology, University of Washington, Seattle, WA
Department of Pharmacology, University of Washington, Seattle, WA
Search for more papers by this authorKelly L. Hudkins
Department of Pathology, University of Washington, Seattle, WA
Search for more papers by this authorKimberly J. Riehle
Department of Pathology, University of Washington, Seattle, WA
Department of Surgery, University of Washington, Seattle, WA
Search for more papers by this authorSimon C. Johnson
Department of Pathology, University of Washington, Seattle, WA
Search for more papers by this authorMatthew M. Yeh
Department of Pathology, University of Washington, Seattle, WA
Search for more papers by this authorTheodor K. Bammler
Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA
Search for more papers by this authorRichard P. Beyer
Department of Surgery, University of Washington, Seattle, WA
Search for more papers by this authorCharles E. Alpers
Department of Pathology, University of Washington, Seattle, WA
Search for more papers by this authorNelson Fausto
Department of Pathology, University of Washington, Seattle, WA
Search for more papers by this authorCorresponding Author
Jean S. Campbell
Department of Pathology, University of Washington, Seattle, WA
Correspondence to: Jean S. Campbell, Department of Pathology, University of Washington, Seattle, WA 98195, USA, Tel.: +206-221-5244, Fax: +206-543-3967, E-mail: [email protected]Search for more papers by this authorJocelyn H. Wright
Department of Pathology, University of Washington, Seattle, WA
Search for more papers by this authorMelissa M. Johnson
Department of Pathology, University of Washington, Seattle, WA
Search for more papers by this authorMasami Shimizu-Albergine
Department of Pathology, University of Washington, Seattle, WA
Department of Pharmacology, University of Washington, Seattle, WA
Search for more papers by this authorRenay L. Bauer
Department of Pathology, University of Washington, Seattle, WA
Search for more papers by this authorBrian J. Hayes
Department of Pathology, University of Washington, Seattle, WA
Search for more papers by this authorJames Surapisitchat
Department of Pathology, University of Washington, Seattle, WA
Department of Pharmacology, University of Washington, Seattle, WA
Search for more papers by this authorKelly L. Hudkins
Department of Pathology, University of Washington, Seattle, WA
Search for more papers by this authorKimberly J. Riehle
Department of Pathology, University of Washington, Seattle, WA
Department of Surgery, University of Washington, Seattle, WA
Search for more papers by this authorSimon C. Johnson
Department of Pathology, University of Washington, Seattle, WA
Search for more papers by this authorMatthew M. Yeh
Department of Pathology, University of Washington, Seattle, WA
Search for more papers by this authorTheodor K. Bammler
Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA
Search for more papers by this authorRichard P. Beyer
Department of Surgery, University of Washington, Seattle, WA
Search for more papers by this authorCharles E. Alpers
Department of Pathology, University of Washington, Seattle, WA
Search for more papers by this authorNelson Fausto
Department of Pathology, University of Washington, Seattle, WA
Search for more papers by this authorCorresponding Author
Jean S. Campbell
Department of Pathology, University of Washington, Seattle, WA
Correspondence to: Jean S. Campbell, Department of Pathology, University of Washington, Seattle, WA 98195, USA, Tel.: +206-221-5244, Fax: +206-543-3967, E-mail: [email protected]Search for more papers by this authorAbstract
Cirrhosis is the primary risk factor for the development of hepatocellular carcinoma (HCC), yet the mechanisms by which cirrhosis predisposes to carcinogenesis are poorly understood. Using a mouse model that recapitulates many aspects of the pathophysiology of human liver disease, we explored the mechanisms by which changes in the liver microenvironment induce dysplasia and HCC. Hepatic expression of platelet-derived growth factor C (PDGF-C) induces progressive fibrosis, chronic inflammation, neoangiogenesis and sinusoidal congestion, as well as global changes in gene expression. Using reporter mice, immunofluorescence, immunohistochemistry and liver cell isolation, we demonstrate that receptors for PDGF-CC are localized on hepatic stellate cells (HSCs), which proliferate, and transform into myofibroblast-like cells that deposit extracellular matrix and lead to production of growth factors and cytokines. We demonstrate induction of cytokine genes at 2 months, and stromal cell-derived hepatocyte growth factors that coincide with the onset of dysplasia at 4 months. Our results support a paracrine signaling model wherein hepatocyte-derived PDGF-C stimulates widespread HSC activation throughout the liver leading to chronic inflammation, liver injury and architectural changes. These complex changes to the liver microenvironment precede the development of HCC. Further, increased PDGF-CC levels were observed in livers of patients with nonalcoholic fatty steatohepatitis and correlate with the stage of disease, suggesting a role for this growth factor in chronic liver disease in humans. PDGF-C transgenic mice provide a unique model for the in vivo study of tumor–stromal interactions in the liver.
Abstract
What's new?
Hepatocellular carcinoma (HCC) is a deadly disease, with a small percentage of patients qualifying for liver resection or transplantation, the only potentially curative treatments. Improvements in treatment and prevention, however, may be possible through a better understanding of how cirrhosis predisposes individuals to HCC. This study implicates platelet derived growth factor-C (PDGF-C) as a possible driver of stromal changes that lead to epithelial neoplasia in the liver. In transgenic mice, hepatic PDGF-C expression altered the liver microenvironment, promoting carcinogenesis. The transgenic PDGF-C pre-clinical HCC model may be useful for testing novel therapies that target the hepatic tumor microenvironment.
Supporting Information
Additional Supporting Information may be found in the online version of this article.
Filename | Description |
---|---|
ijc28421-sup-0001-suppfiglegends.docx17 KB | Supplementry Figure Legends |
ijc28421-sup-0002-supptbls.docx29.4 KB | Supplementry Tables |
ijc28421-sup-0003-suppfigs.pdf1.5 MB | Supplementry Figures |
ijc28421-sup-0004-suppmet.pdf182.9 KB | Supplementry Methods |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1 Jemal A, Ward E, Thun M. Declining death rates reflect progress against cancer. PLoS One 2010; 5: e9584.
- 2 Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 2010; 15 (Suppl 4): 14–22.
- 3 Severi T, vanMalenstein H, Verslype C, et al. Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets. Acta Pharmacol Sin 2010; 31: 1409–20.
- 4 Weiler-Normann C, Herkel J, Lohse AW. Mouse models of liver fibrosis. Z Gastroenterol 2007; 45: 43–50.
- 5 Denda A, Kitayama W, Kishida H, et al. Development of hepatocellular adenomas and carcinomas associated with fibrosis in C57BL/6J male mice given a choline-deficient, L-amino acid-defined diet. Jpn J Cancer Res 2002; 93: 125–32.
- 6 Campbell JS, Hughes SD, Gilbertson DG, et al. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci USA 2005; 102: 3389–94.
- 7 Fausto N, Campbell JS. Mouse models of hepatocellular carcinoma. Semin Liver Dis 2010; 30: 87–98.
- 8 Hernandez-Gea V, Toffanin S, Friedman SL, et al. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 2013; 144: 512–27.
- 9 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646–74.
- 10 Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008; 22: 1276–312.
- 11 Fredriksson L, Li H, Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 2004; 15: 197–204.
- 12 Ikura Y, Morimoto H, Ogami M, et al. Expression of platelet-derived growth factor and its receptor in livers of patients with chronic liver disease. J Gastroenterol 1997; 32: 496–501.
- 13 Pinzani M, Milani S, Herbst H, et al. Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. Am J Pathol 1996; 148: 785–800.
- 14 Stock P, Monga D, Tan X, et al. Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer. Mol Cancer Ther 2007; 6: 1932–41.
- 15 Borkham-Kamphorst E, Kovalenko E, vanRoeyen CR, et al. Platelet-derived growth factor isoform expression in carbon tetrachloride-induced chronic liver injury. Lab Invest 2008; 88: 1090–100.
- 16 Czochra P, Klopcic B, Meyer E, et al. Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. J Hepatol 2006; 45: 419–28.
- 17 Thieringer F, Maass T, Czochra P, et al. Spontaneous hepatic fibrosis in transgenic mice overexpressing PDGF-A. Gene 2008; 423: 23–8.
- 18 Anderberg C, Li H, Fredriksson L, et al. Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts. Cancer Res 2009; 69: 369–78.
- 19 Bandapalli OR, Macher-Goeppinger S, Schirmacher P, et al. Paracrine signalling in colorectal liver metastases involving tumor cell-derived PDGF-C and hepatic stellate cell-derived PAK-2. Clin Exp Metastasis 2012; 29: 409–17.
- 20 Crawford Y, Kasman I, Yu L, et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009; 15: 21–34.
- 21
Johnson S,
Rabinovitch P. Ex vivo imaging of excised tissue using vital dyes and confocal microscopy. Curr Protoc Cytom 2012;Chapter 9:Unit 9.39.
10.1002/0471142956.cy0939s61 Google Scholar
- 22 Hamilton TG, Klinghoffer RA, Corrin PD, et al. Evolutionary divergence of platelet-derived growth factor alpha receptor signaling mechanisms. Mol Cell Biol 2003; 23: 4013–25.
- 23 Riehle KJ, Campbell JS, McMahan RS, et al. Regulation of liver regeneration and hepatocarcinogenesis by suppressor of cytokine signaling 3. J Exp Med 2008; 205: 91–103.
- 24 Ebrahimkhani MR, Mohar I, Crispe IN. Cross-presentation of antigen by diverse subsets of murine liver cells. Hepatology 2011; 54: 1379–87.
- 25 DeMinicis S, Seki E, Uchinami H, et al. Gene expression profiles during hepatic stellate cell activation in culture and in vivo. Gastroenterology 2007; 132: 1937–46.
- 26 Eitner F, Bücher E, vanRoeyen C, et al. PDGF-C is a proinflammatory cytokine that mediates renal interstitial fibrosis. J Am Soc Nephrol 2008; 19: 281–9.
- 27 Ding BS, Nolan DJ, Butler JM, et al. Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration. Nature 2010; 468: 310–15.
- 28 Sagmeister S, Drucker C, Losert A, et al. HB-EGF is a paracrine growth stimulator for early tumor prestages in inflammation-associated hepatocarcinogenesis. J Hepatol 2008; 49: 955–64.
- 29 ElTayebi HM, Salah W, ElSayed IH, et al. Expression of insulin-like growth factor-II, matrix metalloproteinases, and their tissue inhibitors as predictive markers in the peripheral blood of HCC patients. Biomarkers 2011; 16: 346–54.
- 30 Camargo CA, Madden JF, Gao W, et al. Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent. Hepatology 1997; 26: 1513–20.
- 31 Wright JH, Modjeski KL, Bielas JH, et al. A random mutation capture assay to detect genomic point mutations in mouse tissue. Nucleic Acids Res 2011; 39: e73.
- 32 Campbell JS, Johnson MM, Bauer RL, et al. Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis. Differentiation 2007; 75: 843–52.
- 33 DeLeve LD. Hepatic microvasculature in liver injury. Semin Liver Dis 2007; 27: 390–400.
- 34 Bolognesi M, Merkel C, Sacerdoti D, et al. Role of spleen enlargement in cirrhosis with portal hypertension. Dig Liver Dis 2002; 34: 144–50.
- 35 May D, Djonov V, Zamir G, et al. A transgenic model for conditional induction and rescue of portal hypertension reveals a role of VEGF-mediated regulation of sinusoidal fenestrations. PLoS One 2011; 6: e21478.
- 36 Tarantino L, Sordelli I, Calise F, et al. Prognosis of patients with spontaneous rupture of hepatocellular carcinoma in cirrhosis. Updates Surg 2011; 63: 25–30.
- 37 Kleiner DE, Brunt EM, VanNatta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313–21.
- 38 Llovet JM, Chen Y, Wurmbach E, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006; 131: 1758–67.
- 39 Paradis V, Bièche I, Dargère D, et al. Molecular profiling of hepatocellular carcinomas (HCC) using a large-scale real-time RT-PCR approach: determination of a molecular diagnostic index. Am J Pathol 2003; 163: 733–41.
- 40 Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359: 1995–2004.
- 41 Duffield JS, Lupher M, Thannickal VJ, et al. Host responses in tissue repair and fibrosis. Annu Rev Pathol 2013; 8: 241–76.
- 42 Canbay A, Feldstein AE, Higuchi H, et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 2003; 38: 1188–98.
- 43 Zhan SS, Jiang JX, Wu J, et al. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology 2006; 43: 435–43.
- 44 Wynn TA, Barron L. Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis 2010; 30: 245–57.
- 45 Hoshida Y, Toffanin S, Lachenmayer A, et al. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010; 30: 35–51.
- 46 Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 2006; 25: 3787–800.
- 47 Gotzmann J, Fischer AN, Zojer M, et al. A crucial function of PDGF in TGF-beta-mediated cancer progression of hepatocytes. Oncogene 2006; 25: 3170–85.
- 48 Okada H, Honda M, Campbell JS, et al. Acyclic retinoid targets platelet-derived growth factor signaling in the prevention of hepatic fibrosis and hepatocellular carcinoma development. Cancer Res2012; 72: 4459–71.
- 49 Awuah PK, Nejak-Bowen KN, Monga SP. Role and regulation of PDGFRα signaling in liver development and regeneration. Am J Pathol 2013; 182: 1648–58.
- 50 Engels B, Rowley DA, Schreiber H. Targeting stroma to treat cancers. Semin Cancer Biol 2012; 22: 41–9.